Skip Navigation



JAC Advance Access published online on July 1, 2003

Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkg322
© 2003 by The British Society for Antimicrobial Chemotherapy
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
52/2/287    most recent
dkg322v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Chavalitshewinkoon-Petmitr, P.
Right arrow Articles by Wilairat, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chavalitshewinkoon-Petmitr, P.
Right arrow Articles by Wilairat, P.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2003 The British Society for Antimicrobial Chemotherapy

Brief report

In vitro susceptibility of Trichomonas vaginalis to AT-specific minor groove binding drugs

Porntip Chavalitshewinkoon-Petmitr 1 *, Muhaimin Ramdja 1 , Somsri Kajorndechakiat 1 , Raymond K. Ralph 2 , William A. Denny 3 , and Prapon Wilairat 4

1 Department of Protozoology, Faculty of Tropical Medicine, Mahidol University, Bangkok
2 School of Biological Sciences, The University of Auckland, Auckland
3 Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand
4 Department of Biochemistry, Faculty of Science, Mahidol University, Bangkok, Thailand

* Corresponding author. E-mail: tmppm{at}mahidol.ac.th.

Received 14 July 2002 ; revised 11 February 2003 ; accepted 6 May 2003

Abstract

Trichomoniasis is one of the most common sexually transmitted diseases, with around 120 million world-wide suffering from Trichomonas vaginalis-induced vaginitis every year. Although trichomoniasis can be treated with metronidazole, the prevalence of metronidazole-resistant T. vaginalis seems to be increasing. Since the percentage of AT base pairs in T. vaginalis DNA (71%) is very much higher than in human cells, in this study a series of bisquaternary quinolinium salt compounds with high AT-binding specificity were tested for their antitrichomonal activities. Minimum inhibitory concentrations (MICs) were determined for these compounds against a local strain of T. vaginalis in culture. Among 14 bisquaternary quinolinium compounds tested, an N-ethyl derivative was the most effective drug against T. vaginalis, being nearly as potent (MIC = 0.16 µM) as metronidazole (MIC = 0.096 µM), and with low toxicity towards human cells. The nature of the substitution at the quinolinium quaternary centre appears to be important in terms of effectiveness of bisquaternary compounds against the parasite. In contrast, no clear relationships could be seen for substituents on the quinolinium ring; Me and Cl substituted analogues showed higher activity against trichomonads, whereas OMe, NHMe and NH2 substituents decreased activity.

Keywords: Trichomonas vaginalis, AT-specific drugs, DNA minor groove
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Antimicrob. Agents Chemother.Home page
A. L. Crowell, C. E. Stephens, A. Kumar, D. W. Boykin, and W. E. Secor
Activities of Dicationic Compounds against Trichomonas vaginalis
Antimicrob. Agents Chemother., September 1, 2004; 48(9): 3602 - 3605.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.